Anzeige
Mehr »
Freitag, 27.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QQJB | ISIN: US52886N4060 | Ticker-Symbol:
NASDAQ
27.06.25 | 15:30
0,870 US-Dollar
+1,15 % +0,010
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
LEXARIA BIOSCIENCE CORP Chart 1 Jahr
5-Tage-Chart
LEXARIA BIOSCIENCE CORP 5-Tage-Chart

Aktuelle News zur LEXARIA BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoLexaria Bioscience expands patent portfolio to 50 with new additions5
MoLexaria Bioscience Corp.: Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide148New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine KELOWNA, BC / ACCESS Newswire / June 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...
► Artikel lesen
12.06.Lexaria Bioscience Corp. - 8-K, Current Report2
11.06.Lexaria Bioscience Corp.: Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule207Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events ("AEs") as compared to injected liraglutide (Saxenda(R)) Lexaria has now demonstrated, in distinct human clinical studies...
► Artikel lesen
05.06.Lexaria Bioscience Corp.: Lexaria Attending BIO International Convention211Biotechnology Sector's Premier Strategic Partnering Event KELOWNA, BC / ACCESS Newswire / June 5, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator...
► Artikel lesen
12.05.Lexaria advances drug delivery tech with PharmaCO2
12.05.Lexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company853KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate...
► Artikel lesen
LEXARIA BIOSCIENCE Aktie jetzt für 0€ handeln
28.04.Lexaria Bioscience Corp. - 8-K, Current Report2
28.04.Lexaria Bioscience Corp.: Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock303KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the...
► Artikel lesen
25.04.Lexaria Bioscience announces $2M registered direct offering; shares slip 19%4
25.04.Pre-market Movers: Odyssey Marine Exploration, SES AI, VYNE Therapeutics, The OLB Group, Lexaria Bioscience730OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.30 A.M. ET).In the Green Odyssey Marine Exploration, Inc. (OMEX) is up over...
► Artikel lesen
25.04.Lexaria Bioscience secures $2 million in direct offering3
25.04.Lexaria Bioscience sichert sich 2 Millionen US-Dollar durch Direktplatzierung9
25.04.Lexaria Bioscience Corp.: Lexaria Announces $2 Million Registered Direct Offering of Common Stock263KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that...
► Artikel lesen
23.04.Lexaria Bioscience Corp.: Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology307Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELOWNA, BC / ACCESS Newswire / April 23,...
► Artikel lesen
14.04.Lexaria Bioscience Corp. - 10-Q, Quarterly Report2
03.04.Lexaria schließt Patientenrekrutierung für Diabetes-Medikamentenstudie ab7
03.04.Lexaria completes enrollment for diabetes drug study2
03.04.Lexaria Bioscience Corp.: Lexaria Updates its Ongoing Human Study GLP-1-H24-4272Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria")...
► Artikel lesen
02.04.Lexaria begins human trial for oral diabetes treatment4
Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1